{"id":251814,"date":"2026-09-17T11:12:56","date_gmt":"2026-09-17T05:42:56","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=251814"},"modified":"2026-09-17T11:12:56","modified_gmt":"2026-09-17T05:42:56","slug":"natco-pharma-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Natco Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Natco Pharma share price Rs 810.65 on 17 September 2026, down 0.33%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 206.00 crore. Q2 FY26 base a profit of Rs 518.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Natco Pharma Q2 results date for FY27 is not confirmed, and Natco Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 1,363.00 crore in revenue and a profit of Rs 518.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Natco Pharma Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\">Natco Pharma Ltd.<\/a>, Natco Pharma is a pharmaceutical company that manufactures and markets generic drugs and active pharmaceutical ingredients in India and international markets.. The stock traded at Rs 810.65 on the NSE on 17 September 2026, down 0.33% from the previous close of Rs 813.30, about 33.9% below its 52-week high of Rs 1,226.80 and 2.7% above its 52-week low of Rs 789.00.<\/p>\n<p>What makes the Natco Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,363.00 crore of revenue and a profit of Rs 518.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 735.00 crore and a profit of Rs 206.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=natcopharm_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#When_Is_the_Natco_Pharma_Q2_Results_FY27_Date\" title=\"When Is the Natco Pharma Q2 Results FY27 Date?\">When Is the Natco Pharma Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Natco_Pharma_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Natco Pharma Q2 Results Expectations: What the Market Is Actually Tracking\">Natco Pharma Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Natco_Pharma_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Natco Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Natco Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Natco_Pharma_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Natco Pharma Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Natco Pharma Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Natco_Pharma_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Natco Pharma Quarterly Results Trend Over the Last Four Quarters\">Natco Pharma Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Natco_Pharma_Q2_Results_FY27\" title=\"Key Factors That Could Shape Natco Pharma Q2 Results FY27\">Key Factors That Could Shape Natco Pharma Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Revenue_Roughly_Halved_From_Sep25_to_Dec25\" title=\"Revenue Roughly Halved From Sep25 to Dec25\">Revenue Roughly Halved From Sep25 to Dec25<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Lumpy_Launch-Driven_Revenue_Is_a_Sector-Typical_Pattern\" title=\"Lumpy, Launch-Driven Revenue Is a Sector-Typical Pattern\">Lumpy, Launch-Driven Revenue Is a Sector-Typical Pattern<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#A_One-Off_Tax_Adjustment_Lifted_Mar26_Net_Profit\" title=\"A One-Off Tax Adjustment Lifted Mar26 Net Profit\">A One-Off Tax Adjustment Lifted Mar26 Net Profit<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Natco_Pharma_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Natco Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print\">Natco Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Natco_Pharma_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Natco Pharma Q2 Results Are Announced\">What Investors Should Watch When Natco Pharma Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Natco_Pharma_Q2_Results_FY27\" title=\"Conclusion on Natco Pharma Q2 Results FY27\">Conclusion on Natco Pharma Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#FAQs_on_Natco_Pharma_Q2_Results_FY27\" title=\"FAQs on Natco Pharma Q2 Results FY27\">FAQs on Natco Pharma Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#What_is_the_Natco_Pharma_Q2_results_date_for_FY27\" title=\"What is the Natco Pharma Q2 results date for FY27?\">What is the Natco Pharma Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Natco_Pharma_Q2_results_2026_cover\" title=\"What quarter do the Natco Pharma Q2 results 2026 cover?\">What quarter do the Natco Pharma Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#What_were_the_Natco_Pharma_Q1_FY27_results\" title=\"What were the Natco Pharma Q1 FY27 results?\">What were the Natco Pharma Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#What_were_Natco_Pharma_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Natco Pharma Q2 FY26 results in the September 2025 quarter?\">What were Natco Pharma Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Natco_Pharma_Q2_results_expectations_this_quarter\" title=\"What are the main Natco Pharma Q2 results expectations this quarter?\">What are the main Natco Pharma Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#What_is_Natco_Pharma_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Natco Pharma share price today ahead of the Q2 earnings?\">What is Natco Pharma share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/natco-pharma-q2-results-fy27-preview-date-expectations\/#Is_Natco_Pharma_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Natco Pharma a good stock to buy before the Q2 results?\">Is Natco Pharma a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Natco_Pharma_Q2_Results_FY27_Date\"><\/span><strong>When Is the Natco Pharma Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Natco Pharma Q2 results date for FY27 is not confirmed. As of 17 September 2026, Natco Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Natco Pharma Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/jio-financial-services-q2-results-fy27-preview-date-expectations\">Jio Financial Services Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>The Natco Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Natco Pharma.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Natco_Pharma_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Natco Pharma Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Natco Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Natco Pharma. The Natco Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>Natco Pharma Q2 results for the September 2026 quarter will be measured against a recent history marked by sharp swings. Revenue fell from Rs 1,363 crore in Sep25 to Rs 647 crore in Dec25, roughly halving, before settling near Rs 735-739 crore in Mar26 and Jun26, while operating margin moved from 42% down to as low as 17% over the same stretch. That kind of swing is a familiar pattern heading into the Natco Pharma Q2 results.<\/p>\n<p>This kind of revenue lumpiness is consistent with Natco&#8217;s known pattern of large but time-limited generic launches, where an exclusivity window can lift a single quarter&#8217;s sales well above the underlying run rate before tapering off in the following quarters. Mar26 also carried an unusual tax rate of around -62%, which appears to be a one-off tax credit or adjustment, and it lifted net profit to Rs 269 crore even though operating profit that quarter (Rs 128 crore) was lower than Dec25. None of the five quarters reviewed showed a net loss, and this context is useful background for the Natco Pharma Q2 results.<\/p>\n<p>Because of this history, the Natco Pharma Q2 results for the September 2026 quarter are best read with the sector&#8217;s lumpy, launch-driven revenue pattern in mind rather than expecting a straight-line continuation of any single prior quarter. The swings seen from Sep25 to Dec25 reflect a known industry dynamic rather than an operational problem, and that distinction matters for how the Natco Pharma Q2 results are interpreted. Overall profitability metrics, including return on equity near 17.1%, still point to an established, well-run business.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Natco Pharma Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Natco_Pharma_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Natco Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Natco Pharma Ltd. reported revenue of Rs 735.00 crore in Q1 FY27, down 44.70% from Rs 1,329.00 crore in Q1 FY26, and a profit of Rs 206.00 crore at the net level, down 57.08% from Rs 480.00 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/jk-paper-q2-results-fy27-preview-date-expectations\">JK Paper Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>Sequentially, revenue was down 0.54% over the March 2026 quarter figure of Rs 739.00 crore, and net profit was down 23.42% from Rs 269.00 crore in Q4 FY26. Operating margin stood at 43.0% in Q1 FY27 against 42.0% in the September 2025 quarter, which is the comparison the Natco Pharma Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Natco_Pharma_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Natco Pharma Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Natco Pharma Ltd. reported revenue of Rs 1,363.00 crore and a profit of Rs 518.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Natco Pharma Q2 results preview.<\/p>\n<p>Net profit in that base quarter was above the Rs 206.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 1,363.00 crore sits above the Rs 735.00 crore of the June 2026 quarter, which frames how much sequential movement the Natco Pharma Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Natco_Pharma_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Natco Pharma Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>1,363.00<\/td>\n<td>518.00<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>647.00<\/td>\n<td>151.00<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>739.00<\/td>\n<td>269.00<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>735.00<\/td>\n<td>206.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Natco Pharma Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 647.00 crore to Rs 1,363.00 crore, and net profit from Rs 151.00 crore to Rs 518.00 crore. That spread is the honest context for the Natco Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Natco_Pharma_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Natco Pharma Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Natco Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Natco Pharma has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Roughly_Halved_From_Sep25_to_Dec25\"><\/span><strong>Revenue Roughly Halved From Sep25 to Dec25<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue fell from Rs 1,363 crore in Sep25 to Rs 647 crore in Dec25, a drop of roughly half, with operating margin declining from 42% to 25% over the same period. This kind of move is typical for generic pharmaceutical companies following a limited-exclusivity launch, and it is a central data point for the Natco Pharma Q2 results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Lumpy_Launch-Driven_Revenue_Is_a_Sector-Typical_Pattern\"><\/span><strong>Lumpy, Launch-Driven Revenue Is a Sector-Typical Pattern<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Natco Pharma&#8217;s business includes generic drug launches that can carry limited periods of exclusivity, which tends to produce large revenue spikes followed by a step down once that exclusivity period ends. This pattern, rather than any underlying weakness, explains much of the swing between Sep25 and Dec25 and is worth keeping in mind while assessing the Natco Pharma Q2 results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"A_One-Off_Tax_Adjustment_Lifted_Mar26_Net_Profit\"><\/span><strong>A One-Off Tax Adjustment Lifted Mar26 Net Profit<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Mar26 showed an unusual effective tax rate near -62%, likely reflecting a one-off tax credit, which helped push net profit to Rs 269 crore despite operating profit of Rs 128 crore being lower than the prior quarter. This kind of one-time item is useful context for the Natco Pharma Q2 results, since it affected the tax line rather than core operating performance.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Natco_Pharma_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Natco Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Natco Pharma share price today is Rs 810.65 on the NSE, down Rs 2.65 or 0.33% from the previous close of Rs 813.30 on 17 September 2026, ahead of the Natco Pharma Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (17 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>NATCOPHARM<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 810.65<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 1,226.80<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 789.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 14513 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>12.66<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>1.57<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 64.02<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 515.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.08<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>17.1%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 896.19<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 944.37<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>24.02<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades below both its 50-day average of Rs 896.19 and its 200-day average of Rs 944.37, with a 14-day RSI of 24.02. None of this is a view on where the shares go once the Natco Pharma Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Natco Pharma Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Natco_Pharma_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Natco Pharma Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Natco Pharma Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 1,363.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 518.00 crore in that same quarter<\/li>\n<li>Operating margin against 43.0% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Natco Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Natco_Pharma_Q2_Results_FY27\"><\/span><strong>Conclusion on Natco Pharma Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Natco Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Natco Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Natco Pharma Q2 results FY27 print faces a base of Rs 1,363.00 crore in revenue and a profit of Rs 518.00 crore, with the most recent quarter having delivered Rs 735.00 crore and a profit of Rs 206.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Natco Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Natco_Pharma_Q2_Results_FY27\"><\/span><strong>FAQs on Natco Pharma Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Natco_Pharma_Q2_results_date_for_FY27\"><\/span><strong>What is the Natco Pharma Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Natco Pharma Q2 results date for FY27 is not confirmed. Natco Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Natco_Pharma_Q2_results_2026_cover\"><\/span><strong>What quarter do the Natco Pharma Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Natco Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Natco Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Natco Pharma Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Natco_Pharma_Q1_FY27_results\"><\/span><strong>What were the Natco Pharma Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Natco Pharma Ltd. reported revenue of Rs 735.00 crore in Q1 FY27 and a profit of Rs 206.00 crore at the net level. Revenue was down 44.70% versus Q1 FY26 and net profit was down 57.08% from Rs 480.00 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Natco_Pharma_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Natco Pharma Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Natco Pharma Ltd. reported revenue of Rs 1,363.00 crore and a profit of Rs 518.00 crore in Q2 FY26. Operating margin was 42.0%. Those figures form the base for the Natco Pharma Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Natco_Pharma_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Natco Pharma Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Natco Pharma Q2 results expectations centre on revenue against the Rs 1,363.00 crore base, net profit against a profit of Rs 518.00 crore, operating margin against 43.0% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Natco_Pharma_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Natco Pharma share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Natco Pharma share price is Rs 810.65 on the NSE as of 17 September 2026, down 0.33% from Rs 813.30. The stock is about 33.9% below its 52-week high of Rs 1,226.80 and 2.7% above its 52-week low of Rs 789.00, at a market capitalisation of Rs 14513 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Natco_Pharma_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Natco Pharma a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Natco Pharma Ltd. The stock trades at a price-to-book ratio of 1.57 with a return on equity of 17.1%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Natco Pharma Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Natco Pharma Q2 results date for FY27 is not confirmed. Natco Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Natco Pharma Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Natco Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Natco Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Natco Pharma Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Natco Pharma Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Natco Pharma Ltd. reported revenue of Rs 735.00 crore in Q1 FY27 and a profit of Rs 206.00 crore at the net level. Revenue was down 44.70% versus Q1 FY26 and net profit was down 57.08% from Rs 480.00 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Natco Pharma Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Natco Pharma Ltd. reported revenue of Rs 1,363.00 crore and a profit of Rs 518.00 crore in Q2 FY26. Operating margin was 42.0%. Those figures form the base for the Natco Pharma Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Natco Pharma Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Natco Pharma Q2 results expectations centre on revenue against the Rs 1,363.00 crore base, net profit against a profit of Rs 518.00 crore, operating margin against 43.0% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Natco Pharma share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Natco Pharma share price is Rs 810.65 on the NSE as of 17 September 2026, down 0.33% from Rs 813.30. The stock is about 33.9% below its 52-week high of Rs 1,226.80 and 2.7% above its 52-week low of Rs 789.00, at a market capitalisation of Rs 14513 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Natco Pharma a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Natco Pharma Ltd. The stock trades at a price-to-book ratio of 1.57 with a return on equity of 17.1%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Natco Pharma Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Natco Pharma Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":251811,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[482],"class_list":["post-251814","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results","tag-pharma-sector"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["251811"],"rank_math_title":["Natco Pharma Q2 Preview: Revenue Trends"],"rank_math_description":["Natco Pharma Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Natco Pharma Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/natco-pharma-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/251814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=251814"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/251814\/revisions"}],"predecessor-version":[{"id":251815,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/251814\/revisions\/251815"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/251811"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=251814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=251814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=251814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}